347 related articles for article (PubMed ID: 7524376)
1. Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.
Ben-Izhak O; Stark P; Levy R; Bergman R; Lichtig C
Am J Dermatopathol; 1994 Jun; 16(3):241-6. PubMed ID: 7524376
[TBL] [Abstract][Full Text] [Related]
2. Acral lentiginous melanoma: an immunohistochemical study of 20 cases.
Kim YC; Lee MG; Choe SW; Lee MC; Chung HG; Cho SH
Int J Dermatol; 2003 Feb; 42(2):123-9. PubMed ID: 12709000
[TBL] [Abstract][Full Text] [Related]
3. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.
Zubovits J; Buzney E; Yu L; Duncan LM
Hum Pathol; 2004 Feb; 35(2):217-23. PubMed ID: 14991540
[TBL] [Abstract][Full Text] [Related]
4. Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique.
Plaza JA; Suster D; Perez-Montiel D
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):421-5. PubMed ID: 18091385
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody.
Fernando SS; Johnson S; Bäte J
Pathology; 1994 Jan; 26(1):16-9. PubMed ID: 8165017
[TBL] [Abstract][Full Text] [Related]
6. Epithelial markers in pancreatic carcinoma: immunoperoxidase localisation of DD9, CEA, EMA and CAM 5.2.
Heyderman E; Larkin SE; O'Donnell PJ; Haines AM; Warren PJ; Northeast A; Grant AG
J Clin Pathol; 1990 Jun; 43(6):448-52. PubMed ID: 1696288
[TBL] [Abstract][Full Text] [Related]
7. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunoreactivity of CD-68 and HMB-45 in malignant melanoma, neural tumors and nevi.
Shah IA; Gani OS; Wheler L
Pathol Res Pract; 1997; 193(7):497-502. PubMed ID: 9342756
[TBL] [Abstract][Full Text] [Related]
9. Melanoma cell heterogeneity. A study of two monoclonal antibodies compared with S-100 protein in paraffin sections.
Duray PH; Palazzo J; Gown AM; Ohuchi N
Cancer; 1988 Jun; 61(12):2460-8. PubMed ID: 3365669
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous melanoma with myxoid features: twelve cases with differential diagnosis.
Hitchcock MG; McCalmont TH; White WL
Am J Surg Pathol; 1999 Dec; 23(12):1506-13. PubMed ID: 10584704
[TBL] [Abstract][Full Text] [Related]
11. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.
Boyle JL; Haupt HM; Stern JB; Multhaupt HA
Arch Pathol Lab Med; 2002 Jul; 126(7):816-22. PubMed ID: 12088451
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
13. Epithelial antigens in carcinomas of the ovaries. Relation to histological classification.
Jørgensen A; Nielsen K
APMIS; 1994 Jul; 102(7):533-7. PubMed ID: 7522476
[TBL] [Abstract][Full Text] [Related]
14. CEA reactivity in amelanotic malignant melanoma of the anal canal.
Ben-Izhak O; Lichtig C
Pathol Res Pract; 1993 Nov; 189(9):1071-6; discussion 1077-83. PubMed ID: 8302727
[TBL] [Abstract][Full Text] [Related]
15. The immunoperoxidase localization of tumour markers in ovarian cancer: the value of CEA, EMA, cytokeratin and DD9.
Hammond RH; Bates TD; Clarke DG; Grant AG; Haines AM; Eustace DL; Heyderman E
Br J Obstet Gynaecol; 1991 Jan; 98(1):73-83. PubMed ID: 1705435
[TBL] [Abstract][Full Text] [Related]
16. A metastatic melanoma with an unusual immunophenotypic profile.
Gao Z; Stanek A; Chen S
Am J Dermatopathol; 2007 Apr; 29(2):169-71. PubMed ID: 17414440
[TBL] [Abstract][Full Text] [Related]
17. Primary mucosal malignant melanoma: an immunohistochemical study of 12 cases with comparison to cutaneous and metastatic melanomas.
Fitzgibbons PL; Chaurushiya PS; Nichols PW; Chandrasoma PT; Martin SE
Hum Pathol; 1989 Mar; 20(3):269-72. PubMed ID: 2722176
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry of germ cell and trophoblastic neoplasms.
Niehans GA; Manivel JC; Copland GT; Scheithauer BW; Wick MR
Cancer; 1988 Sep; 62(6):1113-23. PubMed ID: 2457424
[TBL] [Abstract][Full Text] [Related]
19. CEA immunoreactivity in metastatic malignant melanoma.
Selby WL; Nance KV; Park HK
Mod Pathol; 1992 Jul; 5(4):415-9. PubMed ID: 1495947
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens.
Motoyama T; Watanabe T; Okazaki E; Tanaka N; Watanabe H
Acta Cytol; 1995; 39(2):164-70. PubMed ID: 7534025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
